We are live on
!
Find out more
MC
Merck & Co Portfolio holdings
AUM
$349M
1-Year Est. Return
146.07%
This Fund
S&P 500
This Quarter
Est. Return
-15.78%
1 Year Est. Return
+146.07%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$258M
AUM Growth
–
Cap. Flow
+$274M
Cap. Flow
% of AUM
106.31%
Top 10 Holdings %
Top 10 Hldgs %
99.57%
Holding
13
New
13
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$110M |
| 2 |
Personalis
PSNL
|
+$64.8M |
| 3 |
Kymera Therapeutics
KYMR
|
+$34.9M |
| 4 |
Entrada Therapeutics
TRDA
|
+$31.5M |
| 5 |
Alector
ALEC
|
+$13.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Moderna
MRNA
$21.5B
| $96M | 37.19% |
+2,308,190
| New | +$110M |
|
|
2
Personalis
PSNL
$1.39B
| $81.2M | 31.46% |
+14,044,943
| New | +$64.8M |
|
|
3
Kymera Therapeutics
KYMR
$8.75B
| $31.1M | 12.04% |
+772,165
| New | +$34.9M |
|
|
4
Entrada Therapeutics
TRDA
$267M
| $30.1M | 11.66% |
+1,739,768
| New | +$31.5M |
|
|
5
Alector
ALEC
$203M
| $6.7M | 2.6% |
+3,545,719
| New | +$13.3M |
|
6
Sutro Biopharma
STRO
$400M
| $5.01M | 1.94% |
+272,351
| New | +$8.31M |
|
7
Absci
ABSI
$1.41B
| $2.62M | 1.01% |
+998,163
| New | +$3.51M |
|
8
Viridian Therapeutics
VRDN
$2.49B
| $1.79M | 0.69% |
+93,414
| New | +$2.03M |
|
9
Xilio Therapeutics
XLO
$61M
| $1.42M | 0.55% |
+105,983
| New | +$1.46M |
|
|
LVTX
10
DELISTED
LAVA Therapeutics
LVTX
| $1.09M | 0.42% |
+1,149,345
| New | +$1.8M |
|
|
CARM
11
DELISTED
Carisma Therapeutics
CARM
| $617K | 0.24% |
+1,473,240
| New | +$1.21M |
|
|
EVAX
12
Evaxion A/S
EVAX
$25M
| $458K | 0.18% |
+108,456
| New | +$1.07M |
|
|
NEUP
13
Neuphoria Therapeutics
NEUP
$21.1M
| $34.4K | 0.01% |
+10,027
| New | +$35.4K |
|
Similar funds
KFG
LAS
BC
EPW
NC
1CP
SMC
AWA
Merck & Co's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Merck & Co, which disclosed 13 positions worth $258M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Moderna: 2,308,190 shares worth $96M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Merck & Co's largest Q4 2024 buy was Moderna: 2,308,190 shares worth $96M.
- Merck & Co's ten largest holdings make up 100% of its $258M portfolio in Q4 2024.
- Merck & Co disclosed 13 positions in Q4 2024, its first 13F filing on record.
Based on Merck & Co's 13F filing for Q4 2024, filed 14 Feb 2025.